ETHERNA IMMUNOTHERAPIES

Their core work

eTheRNA is a Belgian biotech SME specializing in mRNA-based immunotherapies, with a core focus on therapeutic cancer vaccines using their proprietary TriMix adjuvant platform. They develop mRNA therapeutics for oncology (particularly HPV-related cancers like cervical and head-and-neck) and have expanded into broader mRNA applications including nanomedicine delivery and manufacturing. Their work spans from early discovery through clinical-stage development, with their TIGER project advancing a best-in-class mRNA cancer vaccine toward late-stage clinical trials (Phase 1/2a).

What they specialise in

How they've shifted over time

eTheRNA's H2020 trajectory shows a clear maturation from exploratory participation to clinical-stage leadership. Their earliest involvement (HIVACAR, 2017) was as a participant contributing personalised vaccine expertise to an HIV functional cure consortium — a smaller role with modest funding (€215K). By 2019-2021, they shifted decisively toward oncology mRNA therapeutics with major funding (€5M+ per project), culminating in coordinating TIGER, their own proof-of-principle clinical trial for an mRNA cancer vaccine. The evolution reflects a company moving from platform contributor to clinical-stage biotech leading its own therapeutic programs.

eTheRNA is moving toward late-stage clinical development of mRNA cancer vaccines, suggesting future collaborations will focus on clinical trial execution, regulatory pathways, and commercial-scale mRNA manufacturing.

How they like to work

eTheRNA operates as both a contributor and a leader depending on project maturity — joining large consortia as a specialist partner (HIVACAR, EXPERT) while coordinating their own flagship clinical programs (TIGER). With 36 unique partners across 14 countries from just 3 projects, they work in substantial consortia and maintain a broad network. This pattern suggests a company that builds credibility through consortium participation, then uses that network to assemble and lead its own programs when ready.

eTheRNA has built a wide collaborative network of 36 unique partners spanning 14 countries through just 3 projects, indicating involvement in large, multi-national consortia typical of clinical-stage health research. Their network reach is notably broad for an SME of their size, suggesting strong reputation in the European mRNA therapeutics community.

What sets them apart

eTheRNA's distinctive advantage is the TriMix mRNA adjuvant platform — a proprietary technology that differentiates their cancer vaccines from competing mRNA approaches. Unlike most mRNA companies that emerged during COVID, eTheRNA has been focused on therapeutic (not prophylactic) mRNA vaccines since before the pandemic, giving them deep domain expertise in oncology applications. For consortium builders, they offer a rare combination: SME agility with clinical-stage maturity and proven experience managing €5M+ EU-funded programs.

Highlights from their portfolio

• TIGER
  Their flagship program as coordinator (€5.1M) — proof-of-principle for their TriMix mRNA cancer vaccine targeting HPV-driven cancers, advancing toward Phase 2a clinical trials.
• EXPERT
  Largest single grant (€5.4M) in a major mRNA therapeutics platform project covering manufacturing, nanomedicine delivery, and quality control — positions eTheRNA within the broader European mRNA ecosystem.
• HIVACAR
  Early entry point into EU-funded immunotherapy research, applying their personalised vaccine expertise to the challenging goal of functional HIV cure.